Sankey It
Loading...
Pfizer Inc. FY2024 income statement | Sankey It
Sankey It · PFE
Pfizer Inc. FY2024 income statement
USD · fiscal year ended 2024-12-31
FY2025
FY2024
FY2023
FY2022
FY2021
Quarterly
Annual
comfortable
compact
Hide amounts
Export
Fullscreen
Pfizer Inc. FY2024 income statement
Flow diagram with 8 nodes and 7 flows for Pfizer Inc. FY2024 income statement. Values: Biopharma Segment US$62.4B, Revenue US$63.6B, Cost of Revenue US$21.8B, Gross Profit US$41.8B, Operating Expenses US$25.4B, Operating Income US$16.5B, Other Expense US$8.5B, Net Income US$8B.
Biopharma Segment
US$62.4B
+9% Y/Y
98% of revenue
Revenue
US$63.6B
+7% Y/Y
Cost of Revenue
(US$21.8B)
-25% Y/Y
34% of revenue
Gross Profit
US$41.8B
+38% Y/Y
66% margin
Operating Expenses
(US$25.4B)
+1% Y/Y
40% of revenue
Operating Income
US$16.5B
+211% Y/Y
26% margin
Other Expense
(US$8.5B)
+100% Y/Y
13% of revenue
Net Income
US$8B
+276% Y/Y
13% margin
Net / profit
Inputs
Tax / cost
Copy link
Share on X
Open full screen